BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22913971)

  • 1. Oligodendrogliomas: new insights from the genetics and perspectives.
    Alentorn A; Sanson M; Idbaih A
    Curr Opin Oncol; 2012 Nov; 24(6):687-93. PubMed ID: 22913971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ETV/Pea3 family transcription factor-encoding genes are overexpressed in CIC-mutant oligodendrogliomas.
    Padul V; Epari S; Moiyadi A; Shetty P; Shirsat NV
    Genes Chromosomes Cancer; 2015 Dec; 54(12):725-33. PubMed ID: 26357005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.
    Sahm F; Koelsche C; Meyer J; Pusch S; Lindenberg K; Mueller W; Herold-Mende C; von Deimling A; Hartmann C
    Acta Neuropathol; 2012 Jun; 123(6):853-60. PubMed ID: 22588899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.
    Cahill DP; Louis DN; Cairncross JG
    CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
    Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
    Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
    Yip S; Butterfield YS; Morozova O; Chittaranjan S; Blough MD; An J; Birol I; Chesnelong C; Chiu R; Chuah E; Corbett R; Docking R; Firme M; Hirst M; Jackman S; Karsan A; Li H; Louis DN; Maslova A; Moore R; Moradian A; Mungall KL; Perizzolo M; Qian J; Roldan G; Smith EE; Tamura-Wells J; Thiessen N; Varhol R; Weiss S; Wu W; Young S; Zhao Y; Mungall AJ; Jones SJ; Morin GB; Chan JA; Cairncross JG; Marra MA
    J Pathol; 2012 Jan; 226(1):7-16. PubMed ID: 22072542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
    Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
    Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.
    Reyes-Botero G; Dehais C; Idbaih A; Martin-Duverneuil N; Lahutte M; Carpentier C; Letouzé E; Chinot O; Loiseau H; Honnorat J; Ramirez C; Moyal E; Figarella-Branger D; Ducray F;
    Neuro Oncol; 2014 May; 16(5):662-70. PubMed ID: 24353325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
    Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A
    Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.
    Figarella-Branger D; Mokhtari K; Dehais C; Jouvet A; Uro-Coste E; Colin C; Carpentier C; Forest F; Maurage CA; Vignaud JM; Polivka M; Lechapt-Zalcman E; Eimer S; Viennet G; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Loussouarn D; Lacroix C; Rigau V; Laquerrière A; Vandenbos F; Michalak S; Sevestre H; Peoch M; Labrousse F; Christov C; Kemeny JL; Chenard MP; Chiforeanu D; Ducray F; Idbaih A;
    Neuro Oncol; 2014 Sep; 16(9):1244-54. PubMed ID: 24723566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors.
    Chan AK; Pang JC; Chung NY; Li KK; Poon WS; Chan DT; Shi Z; Chen L; Zhou L; Ng HK
    Mod Pathol; 2014 Mar; 27(3):332-42. PubMed ID: 24030748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Network-based analysis of oligodendrogliomas predicts novel cancer gene candidates within the region of the 1p/19q co-deletion.
    Gladitz J; Klink B; Seifert M
    Acta Neuropathol Commun; 2018 Jun; 6(1):49. PubMed ID: 29890994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma.
    Sathornsumetee S; Cheunsuchon P; Sangruchi T
    World Neurosurg; 2016 Jul; 91():518-523.e1. PubMed ID: 26960282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion.
    Lasocki A; Buckland ME; Molinaro T; Xie J; Gaillard F
    AJNR Am J Neuroradiol; 2023 Nov; 44(11):1270-1274. PubMed ID: 37884300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of chromosome 1p/19q in oligodendroglial tumors: refinement of chromosomal critical regions and evaluation of internexin immunostaining as a surrogate marker.
    Buckley PG; Alcock L; Heffernan J; Woods J; Brett F; Stallings RL; Farrell MA
    J Neuropathol Exp Neurol; 2011 Mar; 70(3):177-82. PubMed ID: 21293300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas.
    Garton ALA; Kinslow CJ; Rae AI; Mehta A; Pannullo SC; Magge RS; Ramakrishna R; McKhann GM; Sisti MB; Bruce JN; Canoll P; Cheng SK; Sonabend AM; Wang TJC
    J Neurosurg; 2020 May; 134(5):1357-1367. PubMed ID: 32384274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in CIC and FUBP1 contribute to human oligodendroglioma.
    Bettegowda C; Agrawal N; Jiao Y; Sausen M; Wood LD; Hruban RH; Rodriguez FJ; Cahill DP; McLendon R; Riggins G; Velculescu VE; Oba-Shinjo SM; Marie SK; Vogelstein B; Bigner D; Yan H; Papadopoulos N; Kinzler KW
    Science; 2011 Sep; 333(6048):1453-5. PubMed ID: 21817013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas.
    Kitange G; Misra A; Law M; Passe S; Kollmeyer TM; Maurer M; Ballman K; Feuerstein BG; Jenkins RB
    Genes Chromosomes Cancer; 2005 Jan; 42(1):68-77. PubMed ID: 15472895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity.
    Baumgarten P; Harter PN; Tönjes M; Capper D; Blank AE; Sahm F; von Deimling A; Kolluru V; Schwamb B; Rabenhorst U; Starzetz T; Kögel D; Rieker RJ; Plate KH; Ohgaki H; Radlwimmer B; Zörnig M; Mittelbronn M
    Neuropathol Appl Neurobiol; 2014 Feb; 40(2):205-16. PubMed ID: 24117486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.